GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Singular Genomics Systems Inc (NAS:OMIC) » Definitions » 5-Year Yield-on-Cost %

OMIC (Singular Genomics Systems) 5-Year Yield-on-Cost % : 0.00 (As of Apr. 17, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Singular Genomics Systems 5-Year Yield-on-Cost %?

Singular Genomics Systems's yield on cost for the quarter that ended in Sep. 2024 was 0.00.


The historical rank and industry rank for Singular Genomics Systems's 5-Year Yield-on-Cost % or its related term are showing as below:



OMIC's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.385
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Singular Genomics Systems's 5-Year Yield-on-Cost %

For the Medical Instruments & Supplies subindustry, Singular Genomics Systems's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Singular Genomics Systems's 5-Year Yield-on-Cost % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Singular Genomics Systems's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Singular Genomics Systems's 5-Year Yield-on-Cost % falls into.


;
;

Singular Genomics Systems 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Singular Genomics Systems is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Singular Genomics Systems  (NAS:OMIC) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Singular Genomics Systems 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Singular Genomics Systems's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Singular Genomics Systems Business Description

Traded in Other Exchanges
N/A
Address
3010 Science Park Road, San Diego, CA, USA, 92121
Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.
Executives
Andrew Spaventa director, 10 percent owner, officer: Chief Executive Officer 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Eli N. Glezer officer: Chief Scientific Officer 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Jyotsna Ghai officer: Chief Operating Officer 3010 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Kim P. Kamdar director C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Marcia Eisenberg director C/O 908 DEVICES INC., 645 SUMMER STREET, BOSTON MA 02210
Sam Ropp officer: Chief Commercial Officer 3010 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Michael J Pellini director 222 DUTTON MILL RD, WILLISTOWN PA 19380
Elaine R Mardis director 301 MERRITT 7, NORWALK CT 06851
James E Flynn 10 percent owner, other: *Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
David Daly officer: President and Chief Operating 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Vincent Brancaccio officer: Vice President, HR 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Dalen Meeter officer: Vice President, Finance 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Daralyn Durie officer: General Counsel 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Jorge Velarde officer: Senior Vice President 10931 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
David L Barker director 9885 TOWNE CENTRE DR, SAN DIEGO CA 92121